Please login to the form below

Not currently logged in
Email:
Password:

Celltrion Healthcare

This page shows the latest Celltrion Healthcare news and features for those working in and with pharma, biotech and healthcare.

Celltrion submits application for inhaled COVID-19 antibody treatment

Celltrion submits application for inhaled COVID-19 antibody treatment

Celltrion has announced that it has submitted an Investigational New Drug (IND) application for its inhaled COVID-19 antibody cocktail treatment and plans to begin a global phase 3 clinical trial ... Dr HoUng Kim, head of medical and marketing division

Latest news

  • Celltrion’s investigational mAb cuts COVID-19 recovery time Celltrion’s investigational mAb cuts COVID-19 recovery time

    South Korean-based Celltrion has posted positive data for its investigational COVID-19 targeting monoclonal antibody (mAb) from a phase 2/3 study. ... especially in moderate patients aged 50 years and over,” said HoUng Kim head of medical and marketing

  • Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

    Mundipharma has strengthened its partnership with biopharmaceutical group Celltrion Healthcare by securing rights to its trastuzumab biosimilar. ... Commenting on the partnership, Man Hoon Kim, president and CEO of Celltrion Healthcare, said: “We are

  • Standing out in a crowd Standing out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars. ... PME sat down recently to discuss pricing, market access and regulatory challenges with Ho-Ung Kim, division head of

  • Mundipharma to launch first MabThera biosimilar in EU Mundipharma to launch first MabThera biosimilar in EU

    approval. Developed by South Korean biosimilar specialist Celltrion Healthcare, Truxima is set to be launched in the UK, Germany, Italy, the Netherlands, Belgium, Ireland and Luxembourg by UK-based pharma network

  • Patients 'sceptical' about biosimilars, says EULAR Patients 'sceptical' about biosimilars, says EULAR

    A cost-effective treatment option like biosimilar infliximab will help to decrease the current and extensive burden on healthcare systems across Europe," commented Celltrion chief executive Stanley Hong. ... as $50bn in savings to healthcare systems

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Sustainability
Environment: where does the pharmaceutical industry stand?
...
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...